DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

• Status: Recruiting
• Trial end date: 2021-11-30
• Target enrollment: 0
• Participant gender: Female

Summary

This early phase I trial studies how well dynamic contrast enhanced molecular resonance imaging (DCE-MRI) and technetium-Tc99m sestamibi molecular breast imaging (MBI) work in assessing tumor response to chemotherapy in patients with triple negative breast cancer (TNBC) who are undergoing chemotherapy. Investigational imaging scans such as MBI and DCE-MRI may help researchers predict which patients may respond to treatment.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborators: GE Healthcare; National Cancer Institute (NCI)
• Treatments: Technetium Tc 99m Sestamibi

Criteria

Inclusion Criteria:

• The patient has proven TNBC, defined by standard pathologic assays as negative for estrogen receptor (ER) and progesterone receptor (PR) (< 10% tumor staining) and negative for human epidermal growth factor 2 (HER2) (immunohistochemistry [IHC] score < 3, gene copy number not amplified)

• TNBC patients who are previously untreated and enrolled in the prospective Institutional Review Board (IRB) approved clinical trial: 2014-0185

• Patients who are able to understand and give consent to participating in the study

Exclusion Criteria:

• Is pregnant (confirmed by the patient as imaging clinic standard of care) or nursing mother

• Has lesions involving chest wall

• Has known allergy to Tc99m sestamibi

• Has known contraindications to MRI

• Has contraindication to MRI contrast